CL-ADBA

Information

CL-ADBA is the short form of methyl (S)-2-(1-butyl-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate. It is an analytical reference standard that is structurally similar to known synthetic cannabinoids.

Chemical Properties

Pharmacology and Effects

CL-ADBA is a synthetic cannabinoid belonging to the indazole-3-carboxamide class. It is presumed to act as a potent agonist of cannabinoid CB₁ and CB₂ receptors, producing THC-like effects at low doses. Very limited scientific data are available, and its pharmacological profile has not been fully characterized.

• Mechanism of action: Presumed full agonist at CB₁ and CB₂ receptors
• Receptor targets: Endocannabinoid system
• Potency: High (active at low milligram or sub-milligram range)
• Onset: Rapid, typically within minutes when inhaled
• Duration: 1–3 hours (estimated)
• Reported effects: Cannabis-like euphoria, relaxation, altered perception

Risks and Side Effects

Due to the lack of toxicological studies, the safety profile of CL-ADBA is unknown. Synthetic cannabinoids of this class have been associated with severe and unpredictable adverse reactions, including acute intoxication and fatalities.

• Cardiovascular: Tachycardia, elevated blood pressure
• Neurological: Confusion, dizziness, seizures (reported with related compounds)
• Psychiatric: Anxiety, panic, hallucinations
• Respiratory: Shortness of breath, depression of respiration (possible)
• Toxicity: Uncharacterized; severe effects possible even at low doses
• Dependence potential: Possible, as with other potent synthetic cannabinoids

Warning